Literature DB >> 33982243

Correlation Between Anthropometric Measurements and Non-alcoholic Fatty Liver Disease in Individuals With Obesity Undergoing Bariatric Surgery: Cross-Sectional Study.

Silênio Souza Reis1, Guilherme Hoverter Callejas2, Rodolfo Araújo Marques2, Martinho A Gestic2, Murillo P Utrini2, Felipe D M Chaim2, Almino C Ramos2, Elinton A Chaim2, Everton Cazzo3.   

Abstract

BACKGROUND: We hypothesize that non-alcoholic fatty liver disease (NAFLD) may be significantly associated with waist circumference (WC), neck circumference (NC), hip circumference (HC), and waist-to-hip ratio (WHR).
OBJECTIVES: To analyze correlations between anthropometric parameters and the occurrence and intensity of NAFLD aspects assessed by histopathological examination in individuals undergoing bariatric surgery.
METHODS: This is a cross-sectional study carried out in a tertiary university hospital. Demographic, clinical, anthropometric, laboratory, and histopathological variables were analyzed; uni- and multivariate analyses were performed. Histopathological variables analyzed were findings of liver biopsies collected during surgical procedures.
RESULTS: Of 119 individuals, 105 (88.2%) were female. The mean age was 38.8 ± 9.3 years and the mean BMI was 37.6 ± 3.1 kg/m2. The prevalence of NAFLD histopathological aspects was: steatosis (76.5%), steatohepatitis (49.6%), and fibrosis (51.3%). WC was significantly higher in individuals with steatosis (103.5 ± 9.9 vs. 99.4 ± 8.4; p = 0.03). Individuals with steatohepatitis presented significantly higher BMI (38.2 ± 3.2 vs. 36.7 ± 2.8; p = 0.01), WC (105.3 ± 10.4 vs. 99.6 ± 8.8; p = 0.002), and WHR (1 ± 0.1 vs. 0.9 ± 0.1; p = 0.02). Age (40.6 ± 9.7 vs. 37 ± 8.5; p = 0.03) and hemoglobin A1c (6.5 ± 0.5 vs. 5.6 ± 0.5; p = 0.004) were significantly higher among individuals with fibrosis. A positive correlation was observed between the steatosis intensity and WHR (R = 0.2; p = 0.04). BMI (R = 0.2; p = 0.02) and glucose (R = 0.2; p = 0.009) were independently correlated with the steatohepatitis intensity. Age (R = 0.3; p = 0.04) was independently correlated with the fibrosis intensity.
CONCLUSION: There were significant associations between anthropometric parameters and NAFLD aspects. WC and WHR were associated with steatosis; BMI, WC, and WHR were associated with steatohepatitis. WHR independently correlated with steatosis intensity.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anthropometry; Bariatric surgery; Fatty liver; Non-alcoholic fatty hepatopathy; Obesity

Mesh:

Year:  2021        PMID: 33982243     DOI: 10.1007/s11695-021-05470-2

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  31 in total

Review 1.  Intensive Lifestyle Intervention for Obesity: Principles, Practices, and Results.

Authors:  Victoria L Webb; Thomas A Wadden
Journal:  Gastroenterology       Date:  2017-02-10       Impact factor: 22.682

Review 2.  Body fat distribution and risk of cardiovascular disease: an update.

Authors:  Jean-Pierre Després
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

Review 3.  Non-alcoholic fatty liver disease - A global public health perspective.

Authors:  Zobair M Younossi
Journal:  J Hepatol       Date:  2018-11-09       Impact factor: 25.083

Review 4.  Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity.

Authors:  Amedeo Lonardo; Alessandro Mantovani; Simonetta Lugari; Giovanni Targher
Journal:  Ann Hepatol       Date:  2020-03-21       Impact factor: 2.400

Review 5.  Obesity, Systemic Hypertension, and Pulmonary Hypertension: A Tale of Three Diseases.

Authors:  Abdul Wahab; Amit K Dey; Dhrubajyoti Bandyopadhyay; Veena Katikineni; Rajus Chopra; Karthik S Vedantam; Mithun Devraj; Anil K Chowdary; Keron Navarengom; Carl J Lavie; Anna Kolpakchi; Hani Jneid
Journal:  Curr Probl Cardiol       Date:  2020-05-18       Impact factor: 5.200

Review 6.  Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome.

Authors:  J Bernadette Moore
Journal:  Proc Nutr Soc       Date:  2010-02-17       Impact factor: 6.297

Review 7.  Metabolically healthy versus metabolically unhealthy obesity.

Authors:  Carla Iacobini; Giuseppe Pugliese; Claudia Blasetti Fantauzzi; Massimo Federici; Stefano Menini
Journal:  Metabolism       Date:  2018-11-17       Impact factor: 8.694

8.  Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality.

Authors:  Abel Romero-Corral; Virend K Somers; Justo Sierra-Johnson; Yoel Korenfeld; Simona Boarin; Josef Korinek; Michael D Jensen; Gianfranco Parati; Francisco Lopez-Jimenez
Journal:  Eur Heart J       Date:  2009-11-20       Impact factor: 29.983

Review 9.  Metabolic syndrome: perception or reality?

Authors:  David C W Lau
Journal:  Curr Atheroscler Rep       Date:  2009-07       Impact factor: 5.113

10.  Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy.

Authors:  Carlo Fumagalli; Niccolò Maurizi; Sharlene M Day; Euan A Ashley; Michelle Michels; Steven D Colan; Daniel Jacoby; Niccolò Marchionni; Justin Vincent-Tompkins; Carolyn Y Ho; Iacopo Olivotto
Journal:  JAMA Cardiol       Date:  2020-01-01       Impact factor: 14.676

View more
  2 in total

1.  The value of combining the simple anthropometric obesity parameters, Body Mass Index (BMI) and a Body Shape Index (ABSI), to assess the risk of non-alcoholic fatty liver disease.

Authors:  Maobin Kuang; Guotai Sheng; Chong Hu; Song Lu; Nan Peng; Yang Zou
Journal:  Lipids Health Dis       Date:  2022-10-20       Impact factor: 4.315

2.  Associations between neck circumference and markers of dysglycemia, non-alcoholic fatty liver disease, and dysmetabolism independent of Body Mass Index in an Emirati population.

Authors:  Esphie Grace Fodra Fojas; Adam John Buckley; Nader Lessan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-06       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.